Skip to content

Measurement of Stress During Anesthesia With Pain Detector on Patients Receiving Atropine

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00328900
Enrollment
24
Registered
2006-05-24
Start date
2006-01-31
Completion date
Unknown
Last updated
2012-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fissure in Ano, Hemorrhoids

Keywords

Galvanic skin response, Anesthesia, Atropine

Brief summary

24 patients randomly divided into two groups, one of the groups receiving atropine in addition to the planned anaesthesia. Skin conductance parameters to be compared between the two groups.

Detailed description

Skin conductance (SC), in terms of numbers of skin conduction fluctuations (NSCF), amplitude and mean skin conductance level, reflect the activity in the sympathetic postganglionic cholinergic fibers which innervate the palmar and plantar sweat glands. Skin conductance, especially numbers of skin conductance fluctuations, may be a promising tool to monitor anesthesia. Atropine, an anticholinergic agent, acts as an antagonist on the muscarinic receptors of the sweat glands and inhibits their secretion in a dose-dependent way. The aim of this study was to find out to what degree SC is influenced by i.v. administration of atropine. Study hypothesis: SC is not influenced by i.v. administration of atropine.

Interventions

DRUGAdministration of 0,7 mg of atropine
DEVICEMeasurement of skin conductance with Pain detector

Sponsors

Rikshospitalet University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients in ASA-group 1-2 * Operations (anal fissures, anal fistulas and haemorrhoids) lasting for less than one hour * informed consent * BMI \<30

Exclusion criteria

* Patients using any medication known to influence the autonomous nervous system * Patients with contraindications to atropine (e.i. fibrillation, glaucoma ect) * BMI \>30 * Pregnancy

Design outcomes

Primary

MeasureTime frame
Number of skin conductance fluctuations

Countries

Norway

Contacts

Primary ContactHanne Storm, PhD
hanne.storm@medisin.uio.no+47 23074398

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026